uploads/2018/08/Diagnostics.png

A Performance Overview of Roche’s Diagnostics Division

By

Updated

Revenue trends

Roche’s Diagnostics division consists of Centralized and Point of Care Solutions, Diabetes Care, Molecular Diagnostics, and Tissue Diagnostics. Roche’s Diagnostics division reported revenues of 6.3 billion Swiss francs in the first half, which reflected ~6.0% YoY growth at CER (constant exchange rates).

In EMEA (Europe, Middle East, and Africa), North America, and other regions, Roche’s Diagnostics division generated first-half revenues of 2.3 billion Swiss francs, 1.57 billion Swiss francs, and 2.2 billion Swiss francs, respectively.

Roche’s (RHHBY) Diagnostics division reported revenues of 3.35 billion Swiss francs in the second quarter, reflecting ~7.0% YoY growth at CER. 

Article continues below advertisement

Diabetes care revenue trends

Roche Diagnostics’ diabetes care unit reported revenues of 991.0 million Swiss francs in the first half, which reflected 1.0% YoY growth. In EMEA, North America, and other regions, Roche’s diabetes care unit generated revenues of 613.0 million Swiss francs, 126.0 million Swiss francs, and 252.0 million Swiss francs, respectively. This reflected an ~5.0% decline, 9.0% growth, and 10.0% growth, respectively, on a YoY basis at CER.

In the second quarter, Roche’s diabetes care unit reported revenues of 513.0 million Swiss francs, representing an ~3.0% YoY decline. In the second quarter, in EMEA, North America, and other regions, Roche’s diabetes care division reported revenues of 313.0 million Swiss francs, 70.0 million Swiss francs, and 130.0 million Swiss francs, respectively. This reflected an ~9.0% decline, 3.0% growth, and 10.0% growth, respectively, on a YoY basis at CER.

Recent developments

In July, Roche received the CE Mark for its Accu-Chek Solo micropump system. Roche noted that it would initiate commercialization of Accu-Chek, a novel insulin delivery system in the UK, Austria, Switzerland, and Poland. Roche is conducting clinical trials in multiple European countries with its Accu-Chek insulin delivery system.

Roche’s Accu-Chek is an insulin micropump system with a traditional insulin pump along with an advanced tube-free delivery system. The Accu-Chek pump allows insulin dosing from the remote control or directly from the pump with an option for detachment and reattachment of the pump without insulin waste. The Accu-Chek system also provides connection to Roche’s diabetes care’s digital Accu-Chek Smart Pix system, which provides support from the doctor’s office.

Among Roche’s peers in the diagnostics market, Abbott Laboratories (ABT), Thermo Fisher Scientific (TMO), and Danaher (DHR) reported revenues of $7.8 billion, $6.1 billion, and $5.0 billion, respectively, in the second quarter.

In the final article in this series, we’ll discuss Roche’s Centralized and Point of Care Solutions, molecular diagnostics, and tissue diagnostics units.

Advertisement

More From Market Realist